RAS Targeting Therapies Market, 2031
09 nov. 2021 06h03 HE
|
Research and Markets
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
03 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 sept. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
15 sept. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
11 août 2021 16h01 HE
|
Revolution Medicines, Inc.
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
04 août 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
06 juil. 2021 09h00 HE
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
24 juin 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...